Changes in Liver Function Test During Intensive Phase of Anti-Tuberculosis Treatment
DOI:
https://doi.org/10.70749/ijbr.v3i4.1159Keywords:
Anti-tuberculosis, Liver function test, HepatotoxicityAbstract
Background: Anti-tuberculosis treatment (ATT) has the potential to be hepatotoxic, particularly during the intense phase. It is crucial to keep an eye on liver function tests (LFTs) at this time to avoid problems and guarantee treatment compliance. Objective: To evaluate how liver function test parameters vary in individuals receiving anti-tuberculosis therapy during the intensive phase of treatment. Methodology: A total of 120 patients were included in the two-month intense phase of ATT. Both at baseline and two months later, bilirubin levels and liver enzymes (ALT, AST, and ALP) were measured. In order to collect information on liver dysfunction symptoms, such as fatigue, jaundice, nausea, and stomach pain, patient interviews were also undertaken. A qualitative theme approach was employed in the study to examine patient awareness and experiences. Results: ALT and AST levels increased significantly after the intensive period, going from 34 U/L to 88 U/L and from 30 U/L to 76 U/L, respectively. Abdominal discomfort (17%), nausea (47%), jaundice (21%), exhaustion (60%), and loss of appetite (53%), were among the clinical complaints recorded. Qualitative results showed delayed symptom reporting and low awareness. Conclusion: The results showed a notable increase in liver enzymes during the anti-tuberculosis treatment's intensive phase, suggesting possible liver impairment. Fatigue, nausea, and jaundice were among the frequently reported symptoms, highlighting the significance of keeping an eye on liver function during therapy to avoid problems
Downloads
References
WHO (2011). Global tuberculosis control: WHO Report 2011. WHO document WHO/CDS/TB.
Kaona, F. A., Tuba, M., Siziya, S., & Sikaona, L. (2004). An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health, 4(1). https://doi.org/10.1186/1471-2458-4-68
Wares, D. F., Singh, S., Acharya, A. K., & Dangi, R. (2003). Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. The international journal of tuberculosis and lung disease, 7(4), 327-335. https://www.ingentaconnect.com/content/iuatld/ijtld/2003/00000007/00000004/art00005
WHO (2008). Anti-tuberculosis drug resistance in the world report no. 4. WHO/HTM/TB/2008.394.
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C. (2003). Tuberculosis. The Lancet, 362(9387), 887-899. https://doi.org/10.1016/s0140-6736(03)14333-4
Lingaraja, M., Venugopal, K., Shashibushan, J., & Naik, S. (2015). A study of liver function tests abnormalities in tuberculosis patients under RNTCP-DOTS, VIMS Bellary. People J Sci Res, 8, 28-33. https://www.pjsr.org/jan15_pdf/ResearchArticle/DrMudegoudara_Lingaraja.pdf
Wu, S., Xia, Y., Lv, X., Zhang, Y., Tang, S., Yang, Z., Tu, D., Deng, P., Cheng, S., Wang, X., Yuan, Y., Liu, F., Hu, D., & Zhan, S. (2012). Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China. BMC Public Health, 12(1). https://doi.org/10.1186/1471-2458-12-454
Chih, L., On, A. W., & Huang, Y. (2014). Correlation of antituberculosis drug-related liver injury and liver function monitoring: A 12-year experience of the Taiwan drug relief Foundation. Journal of Food and Drug Analysis, 22(3), 356-362. https://doi.org/10.1016/j.jfda.2013.10.001
Kemenkes, R. I. (2023). Tubesculosis Control Program Report for 2022. In RI Ministry of Health. https://p2p.kemkes.go.id/wp content/uploads/2023/12/FINAL_231123_Layout-TBC_BahasaInggris.pdf
Kementrian Kesehatan Republik Indonesia. (2020). National Tuberculosis Control Guidelines. In Ministry of Health of the Republic of Indonesia (Vol. 110). https://repository.kemkes.go.id/book/124
Ivan banjuradja, G. singh. (2020a). Mechanisms of Hepatotoxicity and Treatment of Tuberculosis in Liver Disorders. Article Review. Indonesia Journal Chest, 7(2), 55–64.
Kim, J., Nam, W., Kim, S., Kwon, O., Seung, E., Jo, J., Shresha, R., Lee, T., Jeon, T., Ki, S., Lee, H., & Lee, S. (2017). Mechanism investigation of rifampicin-induced liver injury using comparative Toxicoproteomics in mice. International Journal of Molecular Sciences, 18(7), 1417. https://doi.org/10.3390/ijms18071417
Come, Y. F., Buntoro, I. F., Setiono, K. W., & Setianingrum, E. L. (2023). Pengaruh Pemberian Terapi Obat anti Tubekulosis Fase Intensif Terhadap Kadar hemoglobin pada Penderita Tuberkulosis Di Kota Kupang. Cendana Medical Journal (CMJ), 11(1), 24-32. https://doi.org/10.35508/cmj.v11i1.10515
Chang, K. C., Leung, C. C., Yew, W. W., Lau, T. Y., & Tam, C. M. (2008). Hepatotoxicity of Pyrazinamide. American Journal of Respiratory and Critical Care Medicine, 177(12), 1391-1396. https://doi.org/10.1164/rccm.200802-355oc
Chih, L.H., Zhang, S., Zhang, M. (2014). Patterns of liver function test abnormalities during anti-TB therapy. BMC Infect Dis, 14, 212.
Huang, Y., Chern, H., Su, W., Wu, J., Lai, S., Yang, S., Chang, F., & Lee, S. (2002). Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 35(4), 883-889. https://doi.org/10.1053/jhep.2002.32102
Kim, H.J., Kim, Y.S., Kim, S.I., Park, Y.S., Yoon, H.I., Lee, C.T., Lee, J.H. (2017). The incidence and risk factors of hepatotoxicity induced by antituberculosis drugs. Respirology, 22(2), 361–368.
Lingaraja, M., Kaleem, A., Mujeeb, S., Haroon, K. (2015). Evaluation of hepatotoxicity in pulmonary tuberculosis patients undergoing DOTS therapy. J Clin Diagn Res, 9(10), FC01–FC04.
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., Bernardo, J., Venkataramanan, R., & Sterling, T. R. (2006). An official ATS statement: Hepatotoxicity of Antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 174(8), 935-952. https://doi.org/10.1164/rccm.200510-1666st
Wu, S., Lin, J., Pan, W. (2012). Hepatotoxicity of first-line anti-TB drugs and monitoring liver function during treatment. Clin Respir J, 6(3), 167–172.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
